Keyphrases
Molecular Pathways
100%
Indoleamine 2,3-dioxygenase 1 (IDO1)
100%
Cancer Immunotherapy
100%
Tryptophan 2,3-dioxygenase (TDO2)
100%
Pathway Targeting
100%
Kynurenine
60%
Tryptophan
40%
IDO2
40%
Clinical Trials
20%
Immunosuppression
20%
Non-small Cell Lung Cancer (NSCLC)
20%
T Cell Apoptosis
20%
Therapeutic Targeting
20%
Current Therapeutics
20%
Melanoma
20%
Glioblastoma
20%
Metastatic Disease
20%
Metabolic Function
20%
Effector T Cells
20%
Regulatory T Cells
20%
Nicotinamide Adenine Dinucleotide (NAD+)
20%
Immune Checkpoint
20%
Rate-limiting Step
20%
Rapidly Evolving
20%
Clinical Grade
20%
Catabolic
20%
Compensatory Changes
20%
Rapid Development
20%
Kynurenine Pathway
20%
Enzymatic Reaction
20%
Recent Growth
20%
Therapeutic Inhibitors
20%
Tryptophan Catabolism
20%
Immunotherapeutic Intervention
20%
Spontaneous Reaction
20%
Immunotherapy Efficacy
20%
Peptide Vaccine
20%
Energetic Substrates
20%
Breast Cancer Disease
20%
Indoximod
20%
INCB024360
20%
Cancer Immunotherapeutics
20%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Indoleamine 2,3 Dioxygenase
100%
Tryptophan 2,3 Dioxygenase
100%
Immunotherapy
100%
Tryptophan
80%
Kynurenine
80%
Clinical Trial
20%
Breast Cancer
20%
Glioblastoma
20%
Melanoma
20%
Immunosuppressive Agent
20%
Indoximod
20%
4 Amino N (3 Chloro 4 Fluorophenyl) N' Hydroxy 1,2,5 Oxadiazole 3 Carboximidamide
20%
Adenosine Triphosphate
20%
Biochemistry, Genetics and Molecular Biology
Dioxygenase
100%
Cancer Immunotherapy
100%
Indoleamine 2,3-dioxygenase
100%
Tryptophan
100%
Tryptophan 2,3-dioxygenase
60%
Kynurenine
60%
Kynurenine Pathway
20%
Clinical Trial
20%
Immune Checkpoints
20%
Enzyme
20%
Energy Transfer
20%
Adenosine Triphosphate
20%
T Cell
20%
Regulatory T Cell
20%
Programmed Cell Death
20%